Kaneka Corporation V Designs For Health Inc

Court Listener

Automated Summary

Key Facts

This is a patent infringement action where Kaneka Corporation sued Designs for Health, Inc. and American River Nutrition LLC for infringement of U.S. Patent No. 7,829,080, which covers a stabilization method of reduced Coenzyme Q10. The patent's asserted claims require a QH ratio of at least 90 weight percent. After a bench trial in May-June 2024 regarding original products, the case proceeded to a second phase about reformulated products from 2023. Kaneka filed a motion for preliminary injunction on March 15, 2025, but the court denied the motion because Triclinic testing showed most lots had QH ratios below 90%, only one lot exceeded 90% but was unrepresentative due to equipment failure, and accelerated stability testing did not reliably predict ambient conditions. The defendants raised a substantial question as to infringement by the reformulated CoQnol 100 and CoQnol 200 products.

Issues

  • Whether the plaintiff has made a clear showing of infringement necessary to justify preliminary injunctive relief, considering the defendants raised a substantial question as to infringement by the reformulated products
  • Whether the defendants' reformulated CoQnol 100 and CoQnol 200 products meet the 90% QH ratio limitation in claims 5 and 15 of U.S. Patent No. 7,829,080, which requires that the proportion of reduced CoQ10 relative to total CoQ10 is not less than 90 weight percent

Holdings

The court denied plaintiff Kaneka Corporation's motion for a preliminary injunction in this patent infringement action. The court found that the defendants raised a substantial question as to infringement by the reformulated CoQnol 100 and CoQnol 200 products, and that Kaneka failed to make a clear showing that it is entitled to preliminary injunctive relief. The court's findings on infringement are not binding with regard to further proceedings, including the parties' submission of proposed findings of fact and conclusions of law on the ultimate merits and damages issues.

Remedies

The court denied Kaneka Corporation's motion for a preliminary injunction restraining and permanently enjoining Defendants from engaging in the manufacture, sale, offer for sale, or importing into the United States any products that infringe the '080 Patent. The court found that the motion for a permanent injunction was premature at this stage and will be considered after the court issues its findings of fact and conclusions of law on the defendants' liability for the reformulated products and the amount of damages to which Kaneka is entitled.

Legal Principles

A preliminary injunction is an extraordinary remedy that may only be awarded upon a clear showing that the plaintiff is entitled to such relief. A plaintiff seeking a preliminary injunction must establish that he is likely to succeed on the merits, that he is likely to suffer irreparable harm in the absence of preliminary relief, that the balance of equities tips in his favor, and that an injunction is in the public interest. Any one factor may give a district court enough reason to exercise its sound discretion by denying an injunction. To prove a likelihood of success on the merits, a patentee must prove that success in establishing infringement is more likely than not. An accused infringer can defeat a showing of likelihood of success on the merits by demonstrating a substantial question of validity or infringement.

Precedent Name

  • Tinnus Enters., LLC v. Telebrands Corp.
  • GeigTech E. Bay LLC v. Lutron Elecs. Co.
  • Trebro Mfg., Inc. v. Firefly Equip., LLC
  • Amazon.com, Inc. v. Barnesandnoble.com, Inc.
  • LifeScan Scotland, Ltd. v. Shasta Techs., LLC
  • W.L. Gore & Associates, Inc. v. Garlock, Inc.
  • SIMO Holdings Inc. v. Hong Kong uCloudlink Network Tech. Ltd.
  • Mass Engineered Design, Inc. v. Ergotron, Inc.
  • Insulet Corp. v. EOFlow, Co.
  • Del. State Sportsmen's Ass'n v. Del. Dep't of Safety & Homeland Sec.
  • Qorvo, Inc. v. Akoustis Techs., Inc.
  • Winter v. Nat. Res. Defense Council, Inc.
  • University of Texas v. Camenisch
  • ABC Corp. I v. P'ship & Unincorporated Ass'n's Identified on Schedule A

Judge Name

William C. Bryson

Passage Text

  • The defendants' original products contained DuoQuinol that was made with a 4 to 2 to 4 ratio of GG to AP to ubiquinone. TD2 at 315:13-16. After a discussion about reformulating their products in June 2023, see PTX 268, the defendants experimented with altering the ratio of GG to AP to ubiquinone to ensure that the conversion of ubiquinone into ubiquinol would stop before the QH ratio reached 90 percent, see PTX 269. The defendants experimented with six different ratios and ultimately settled on the ratio of 4 to 1.5 to 4 of GG to AP to ubiquinone for their reformulated version of DuoQuinol. See PTX 270, DTX 489.
  • In sum, Kaneka has not met its burden to show that it is entitled to a preliminary injunction. First, the only lot that Triclinic found to have a QH ratio higher than 90 percent was Lot 45818, which was not representative of the reformulated CoQnol 200 product. Every other lot tested by Triclinic had a QH ratio below 90 percent. Second, the QH ratio of Lot 35550 exceeded 90 percent only under accelerated conditions in the defendants' stability testing, which does not reliably establish that the QH ratio of the same lot would exceed 90 percent under ambient conditions. Third, Dr. Myerson's infringement analysis that applied the rate of reduction of Lot 35550 (whether calculated through first-and-last-point analysis or linear regression analysis) to other lots and projected a constant rate of reduction over either 18 or 36 months was unreliable.
  • As per the scheduling arrangements made with counsel at the conclusion of the trial, the parties will file simultaneous Proposed Findings of Fact and Conclusions of Law with respect to the liability issues tried in the second phase of this case plus the issues of damages and other remedies as appropriate in light of the court's rulings on liability. The parties' simultaneous opening briefs of no more than 40 pages will be due for filing within 30 days of the date of this order. Simultaneous response briefs of no more than 20 pages will be due for filing within 14 days of the filing of the opening briefs.